^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor) +
    Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    09/20/2017
    Excerpt:
    Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (NSCLC).
    Secondary therapy:
    carboplatin + bisphosphonate bound paclitaxel
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    10/18/2016
    Excerpt:
    TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated:...in combination with bevacizumab, paclitaxel, and carboplatin, for the firstline treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.
    Secondary therapy:
    carboplatin + paclitaxel